Strong Revenue Growth
Seer reported $4.1 million in revenue for Q2 2025, representing a 32% year-over-year growth. The company maintained a robust balance sheet with $263 million in cash, cash equivalents, and investments.
Launch of Proteograph ONE
Seer launched the Proteograph ONE workflow, which more than doubled throughput and reduced run time by approximately 30%. It enables identification of up to 10x more proteins than traditional workflows.
Landmark Study with Korea University
Seer announced a 20,000 sample population scale study with Korea University, the largest of its kind, leveraging advanced proteomics for early cancer detection.
Share Repurchase Program
Seer has repurchased approximately $20 million of its Class A common shares, reducing net total shares outstanding by approximately 13%.
Strong Customer Validation
Validation of Seer's technology continues to grow with 52 customer publications in high-impact journals, highlighting Proteograph's unique capabilities.